In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

Thyroid cancer incidence is increasing throughout the world. Although this appears to be due largely to enhanced detection of early thyroid cancers by the more generalised use of thyroid ultrasound ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

The US FDA’s approval is based on data from the ongoing Phase 2 PHAROS clinical trial (NCT03915951), an open-label, multicenter, single-arm study examining BRAFTOVI+MEKTOVI combination therapy in both ...

Anticancer drug resistance remains a crucial impediment to the care of many patients with cancer. Although the exact mechanisms of resistance may differ for each therapy, common mechanisms of ...